ImClone Investigational Site

Philadelphia, Pennsylvania 19141-3098

0 studies enrolling now · 17 studies all time

What they study most

Advanced Solid Tumors, Cancer, Colorectal Cancer, Fallopian Tube Neoplasms, Hepatocellular Carcinoma, Malignant Solid Tumor, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Peritoneal Neoplasms

Studies at this site

• A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors — Completed
• A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver — Completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy — Completed
• A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma — Completed
• Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy — Completed
• Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy — Completed
• Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer — Stopped early
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer — Completed
• Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma — Stopped early
• Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) — Completed
• Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer — Completed